This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPED2T082_M.jpg
Imara Inc (NASDAQ:IMRA) 19% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Travere Therapeutics Inc (NASDAQ:TVTX) 5% LOWER; announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.
Eargo Inc (NASDAQ:EAR) 3% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time (the Record Date).
Amprius Technologies Inc (NYSE:AMPX) 2% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $14.00.
Reata Pharmaceuticals, Inc. (Nasdaq: NASDAQ:RETA) 1% HIGHER; announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (“NDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
